Supplier
Mayo Clinic Health System-Northwest Wisconsin Region, INC.
Mayo Clinic Health System-Northwest Wisconsin Region, INC. was paid $16.81M by Medicaid between Jan 2018 and Dec 2024, across 434 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 17% of everything it billed.
33Billing provider infoMAYO CLINIC HEALTH SYSTEM-NORTHWEST WISCONSIN REGION, INC.
EAU CLAIRE, WI 54703
EAU CLAIRE, WI 54703
33aNPI1629027578assigned 05/09/2006
33bProvider typePharmacy
28Total paid$16.81M
24GClaims1,098,373
24DCodes billed434
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pharmacy providers in Wisconsin
Rank by total paid#1 of 98
Median peer was paid$4K
This provider vs. median4,784×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BORTNEM, MARK controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 137,077 | $1.79M | |
| 2019 | 129,264 | $1.62M | |
| 2020 | 132,044 | $2.45M | |
| 2021 | 203,585 | $3.67M | |
| 2022 | 172,412 | $2.55M | |
| 2023 | 163,264 | $2.22M | |
| 2024incomplete | 160,727 | $2.52M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 17% | 42,096 | 36,281 | $2.88M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.7% | 14,742 | 13,302 | $953K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.2% | 10,327 | 8,078 | $880K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.3% | 20,256 | 17,329 | $722K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.7% | 13,581 | 12,068 | $625K |
| 80053 | Comprehensive metabolic panel | 3.5% | 26,482 | 22,373 | $587K |
| 87507 | 2.9% | 1,393 | 1,333 | $481K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.5% | 24,040 | 20,502 | $414K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.3% | 70,524 | 52,356 | $386K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 4,359 | 4,011 | $367K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.0% | 10,683 | 9,910 | $339K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.0% | 10,670 | 9,902 | $334K |
422 more codes
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.7% | 30,911 | $293K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 5,511 | $266K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 5,196 | $251K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.3% | 8,223 | $221K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 47,581 | $219K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 16,004 | $175K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,818 | $168K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,191 | $168K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,225 | $158K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,605 | $152K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 5,887 | $125K |
| 87631 | <1% | 1,115 | $121K | |
| 85610 | <1% | 14,557 | $115K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,798 | $113K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,002 | $111K |
| 64483 | <1% | 787 | $105K | |
| 87480 | <1% | 5,645 | $101K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,446 | $98K |
| 87660 | <1% | 5,645 | $94K | |
| 87510 | <1% | 5,647 | $94K | |
| H2012 | Behavioral health day treatment, per hour | <1% | 1,724 | $92K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 224 | $91K |
| 80061 | Lipid panel | <1% | 8,776 | $89K |
| 93308 | <1% | 879 | $85K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,915 | $84K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,876 | $81K |
| 11721 | <1% | 1,977 | $81K | |
| 87653 | <1% | 2,403 | $79K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 4,550 | $77K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 6,740 | $75K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 694 | $74K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,845 | $73K |
| 87070 | <1% | 6,826 | $73K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,381 | $72K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 847 | $69K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,634 | $69K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,379 | $69K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,204 | $68K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,891 | $67K |
| 82948 | <1% | 7,532 | $67K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,250 | $66K |
| 87077 | <1% | 7,759 | $63K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,186 | $57K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,495 | $56K |
| 82728 | <1% | 4,936 | $56K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,837 | $55K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,208 | $52K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 452 | $52K |
| 93296 | <1% | 2,753 | $50K | |
| 84484 | <1% | 6,139 | $49K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,110 | $49K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,863 | $48K |
| 86803 | <1% | 3,675 | $46K | |
| 84439 | <1% | 6,013 | $45K | |
| 80306 | <1% | 3,114 | $45K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 452 | $44K |
| 83605 | <1% | 6,835 | $42K | |
| 81025 | <1% | 4,418 | $42K | |
| 86780 | <1% | 4,555 | $41K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,268 | $41K |
| 80050 | General health panel | <1% | 1,007 | $41K |
| 85027 | <1% | 9,410 | $40K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 710 | $39K |
| 87186 | <1% | 5,902 | $38K | |
| 93321 | <1% | 624 | $37K | |
| 95886 | <1% | 1,366 | $37K | |
| 84702 | <1% | 2,402 | $37K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,638 | $36K |
| G0378 | Hospital observation service, per hour | <1% | 5,358 | $35K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 328 | $35K |
| 81001 | <1% | 10,919 | $34K | |
| 86850 | <1% | 4,101 | $34K | |
| 87340 | <1% | 3,939 | $34K | |
| 82607 | <1% | 3,079 | $34K | |
| 86480 | <1% | 715 | $33K | |
| 88142 | <1% | 1,607 | $32K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 7,807 | $32K |
| 83970 | <1% | 1,365 | $32K | |
| 83880 | <1% | 2,570 | $31K | |
| 86618 | <1% | 2,116 | $31K | |
| 82947 | <1% | 6,046 | $31K | |
| 83735 | <1% | 7,910 | $28K | |
| 86140 | <1% | 7,827 | $28K | |
| 82805 | <1% | 1,588 | $28K | |
| 82565 | <1% | 5,746 | $27K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 711 | $27K |
| 83690 | <1% | 6,834 | $27K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 674 | $27K |
| 82077 | <1% | 3,136 | $26K | |
| Q3014 | Telehealth originating site facility fee | <1% | 4,261 | $26K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,272 | $25K |
| 94060 | <1% | 1,030 | $25K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,659 | $24K |
| 93225 | <1% | 866 | $23K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,043 | $23K |
| 86762 | <1% | 1,848 | $23K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 41 | $23K |
| V5011 | Fitting/orientation/checking of hearing aid | <1% | 113 | $22K |
| 87103 | <1% | 2,400 | $22K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,214 | $21K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 490 | $20K |
| 87040 | <1% | 4,445 | $20K | |
| 71250 | <1% | 905 | $20K | |
| 88342 | <1% | 1,320 | $20K | |
| 20610 | <1% | 1,391 | $20K | |
| 80143 | <1% | 1,957 | $19K | |
| 80179 | <1% | 1,930 | $19K | |
| 83550 | <1% | 2,977 | $18K | |
| 74018 | <1% | 967 | $18K | |
| 82570 | <1% | 4,306 | $17K | |
| 72100 | <1% | 1,124 | $16K | |
| 85379 | <1% | 2,867 | $16K | |
| 93971 | <1% | 863 | $15K | |
| 93017 | <1% | 654 | $15K | |
| 76830 | Ultrasound, transvaginal | <1% | 579 | $15K |
| 93976 | <1% | 525 | $14K | |
| 81003 | <1% | 6,119 | $14K | |
| 93325 | <1% | 780 | $14K | |
| 83540 | <1% | 3,012 | $14K | |
| 82043 | <1% | 3,168 | $13K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 3,290 | $13K |
| 82746 | <1% | 1,271 | $13K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,432 | $12K |
| 97162 | <1% | 2,009 | $12K | |
| 86481 | <1% | 202 | $12K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,760 | $12K |
| 84153 | <1% | 909 | $12K | |
| 72040 | <1% | 362 | $12K | |
| 87999 | <1% | 310 | $12K | |
| 82248 | <1% | 4,496 | $12K | |
| 80076 | <1% | 1,559 | $11K | |
| 84450 | <1% | 3,497 | $11K | |
| 84460 | <1% | 3,048 | $11K | |
| 86376 | <1% | 1,012 | $10K | |
| 83516 | <1% | 1,103 | $10K | |
| 84165 | <1% | 981 | $9K | |
| 82784 | <1% | 845 | $9K | |
| 84146 | <1% | 538 | $9K | |
| J0248 | Injection, remdesivir, 1 mg | <1% | 254 | $9K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 94 | $8K |
| 86038 | <1% | 886 | $8K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 187 | $8K |
| 97161 | <1% | 577 | $7K | |
| 80047 | <1% | 322 | $7K | |
| 86787 | <1% | 1,130 | $7K | |
| 86706 | <1% | 827 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 382 | $7K |
| 86900 | <1% | 3,525 | $7K | |
| 84132 | <1% | 2,157 | $7K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 17 | $7K |
| 70498 | <1% | 91 | $7K | |
| 86901 | <1% | 3,514 | $6K | |
| 20553 | <1% | 143 | $6K | |
| 73502 | <1% | 1,459 | $6K | |
| 73630 | <1% | 2,824 | $6K | |
| 95812 | <1% | 38 | $6K | |
| 85018 | <1% | 3,076 | $6K | |
| 86769 | <1% | 362 | $5K | |
| 94726 | <1% | 843 | $5K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 686 | $5K |
| 80164 | <1% | 513 | $5K | |
| 82950 | <1% | 1,160 | $5K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 646 | $5K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 62 | $5K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,724 | $5K |
| 70496 | <1% | 64 | $5K | |
| 94729 | <1% | 1,018 | $5K | |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | <1% | 274 | $5K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 731 | $5K |
| 88304 | <1% | 645 | $5K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 2,223 | $5K |
| 92134 | <1% | 3,946 | $5K | |
| 82803 | <1% | 300 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 922 | $5K |
| 93226 | <1% | 748 | $5K | |
| 87075 | <1% | 1,008 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,770 | $4K |
| 86334 | <1% | 306 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 546 | $4K |
| 80178 | <1% | 752 | $4K | |
| 85652 | <1% | 2,311 | $4K | |
| 84100 | <1% | 1,564 | $4K | |
| 82550 | <1% | 871 | $4K | |
| 73030 | <1% | 1,862 | $4K | |
| 86364 | <1% | 237 | $3K | |
| 64635 | <1% | 14 | $3K | |
| 82105 | <1% | 300 | $3K | |
| G0249 | Provision of test materials and equipment for home inr monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; includes: provision of materials for use in the home and reporting of test results to physician; testing not occurring more frequently than once a week; testing materials, billing units of service include 4 tests | <1% | 765 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,615 | $3K |
| 90715 | <1% | 670 | $3K | |
| 73130 | <1% | 1,117 | $3K | |
| 88341 | <1% | 101 | $3K | |
| 95910 | <1% | 77 | $3K | |
| 82310 | <1% | 694 | $3K | |
| 73564 | <1% | 2,377 | $3K | |
| 82247 | <1% | 431 | $3K | |
| 73110 | <1% | 939 | $3K | |
| 83521 | <1% | 159 | $3K | |
| 0240U | <1% | 113 | $3K | |
| 73610 | <1% | 1,502 | $3K | |
| 88307 | <1% | 141 | $3K | |
| 88738 | <1% | 129 | $3K | |
| 90837 | Psychotherapy session, about an hour | <1% | 998 | $3K |
| 93229 | <1% | 164 | $3K | |
| 76770 | <1% | 66 | $3K | |
| 93923 | <1% | 133 | $3K | |
| 62323 | <1% | 13 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,465 | $3K |
| 64636 | <1% | 17 | $3K | |
| 84156 | <1% | 974 | $3K | |
| 72110 | <1% | 118 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 30,757 | $2K |
| 97165 | <1% | 205 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 60 | $2K |
| 80069 | <1% | 575 | $2K | |
| 99024 | <1% | 859 | $2K | |
| 70486 | <1% | 67 | $2K | |
| 87478 | <1% | 97 | $2K | |
| 86704 | <1% | 206 | $2K | |
| 84550 | <1% | 907 | $2K | |
| 83001 | <1% | 125 | $2K | |
| 95800 | <1% | 41 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 40 | $2K |
| 64493 | <1% | 14 | $2K | |
| 77002 | <1% | 128 | $2K | |
| 92557 | <1% | 203 | $2K | |
| 86235 | <1% | 28 | $2K | |
| 83615 | <1% | 659 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 208 | $2K |
| 12001 | <1% | 24 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 28 | $2K |
| 94762 | <1% | 27 | $1K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 16 | $1K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 654 | $1K |
| 84155 | <1% | 672 | $1K | |
| 95908 | <1% | 31 | $1K | |
| 82378 | <1% | 105 | $1K | |
| 76882 | <1% | 69 | $1K | |
| 88141 | <1% | 76 | $1K | |
| 74174 | <1% | 16 | $1K | |
| 82533 | <1% | 84 | $1K | |
| 86696 | <1% | 56 | $1K | |
| 86431 | <1% | 223 | $1K | |
| 93280 | <1% | 97 | $948.31 | |
| 64566 | <1% | 20 | $943.67 | |
| 84295 | <1% | 262 | $881.33 | |
| 93351 | <1% | 14 | $858.74 | |
| 95885 | <1% | 53 | $798.32 | |
| 91322 | <1% | 179 | $767.48 | |
| 99205 | Prolong outpt/office vis | <1% | 170 | $755.98 |
| 97116 | <1% | 102 | $747.89 | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 739 | $736.91 |
| 85730 | <1% | 267 | $718.55 | |
| 87529 | <1% | 26 | $705.72 | |
| 86695 | <1% | 56 | $702.14 | |
| 82657 | <1% | 25 | $623.54 | |
| 29581 | <1% | 661 | $617.25 | |
| 51702 | <1% | 322 | $612.74 | |
| 84075 | <1% | 196 | $583.78 | |
| 94618 | <1% | 53 | $559.25 | |
| 90686 | <1% | 559 | $556.59 | |
| 72050 | <1% | 26 | $535.01 | |
| 77091 | <1% | 115 | $504.08 | |
| 76942 | <1% | 768 | $486.55 | |
| 69210 | <1% | 73 | $472.03 | |
| 36591 | <1% | 421 | $467.03 | |
| 93970 | <1% | 27 | $435.06 | |
| 82977 | <1% | 25 | $427.44 | |
| 82010 | <1% | 75 | $424.80 | |
| 96368 | <1% | 15 | $414.29 | |
| 82375 | <1% | 72 | $410.35 | |
| 74178 | <1% | 42 | $407.52 | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 94 | $395.51 |
| 87493 | <1% | 15 | $382.76 | |
| 88108 | <1% | 28 | $379.06 | |
| 97166 | <1% | 29 | $326.18 | |
| 93880 | <1% | 14 | $314.74 | |
| J3490 | Unclassified drugs | <1% | 3,813 | $308.00 |
| 51798 | <1% | 1,388 | $307.32 | |
| 85014 | <1% | 189 | $246.45 | |
| 90480 | <1% | 179 | $245.12 | |
| 64615 | <1% | 92 | $241.88 | |
| 94010 | <1% | 26 | $231.25 | |
| 87205 | <1% | 120 | $228.81 | |
| 82040 | <1% | 79 | $228.64 | |
| 87206 | <1% | 57 | $202.17 | |
| 20552 | <1% | 12 | $201.15 | |
| 96367 | <1% | 24 | $192.18 | |
| 0097U | <1% | 741 | $179.72 | |
| 98968 | <1% | 26 | $179.63 | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 42 | $179.62 |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 44 | $178.76 |
| 96376 | <1% | 2,532 | $175.20 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,863 | $159.37 |
| 36416 | <1% | 7,738 | $159.17 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 19 | $152.46 |
| 82140 | <1% | 14 | $136.81 | |
| 99495 | <1% | 106 | $133.82 | |
| 74019 | <1% | 40 | $121.48 | |
| 83050 | <1% | 70 | $120.26 | |
| 84560 | <1% | 34 | $120.24 | |
| 86705 | <1% | 12 | $118.88 | |
| 87102 | <1% | 31 | $117.11 | |
| J2704 | Injection, propofol, 10 mg | <1% | 21,946 | $109.38 |
| 84520 | <1% | 38 | $101.93 | |
| 76376 | <1% | 586 | $92.53 | |
| 84145 | <1% | 29 | $91.00 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 79 | $89.21 |
| 73080 | <1% | 161 | $77.53 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 609 | $76.47 |
| 77065 | Tomosynthesis, mammo | <1% | 30 | $71.30 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,137 | $68.90 |
| 72170 | <1% | 76 | $68.69 | |
| 97035 | <1% | 56 | $52.25 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,607 | $51.16 |
| 90656 | <1% | 26 | $49.22 | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 28 | $38.85 |
| C1769 | Guide wire | <1% | 1,470 | $33.95 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 37 | $33.83 |
| 83718 | <1% | 49 | $32.59 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,243 | $31.18 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,972 | $30.56 |
| 73590 | <1% | 82 | $30.41 | |
| 90662 | <1% | 459 | $27.93 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,259 | $21.95 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 405 | $21.80 |
| 0764T | <1% | 45 | $21.42 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,177 | $21.24 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 954 | $20.30 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,372 | $20.08 |
| 11102 | <1% | 14 | $18.99 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 2,755 | $16.78 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,185 | $15.86 |
| 82465 | <1% | 36 | $12.74 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 6,646 | $11.55 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 809 | $10.94 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,341 | $10.86 |
| 99496 | <1% | 92 | $8.24 | |
| 0004A | <1% | 38 | $5.78 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,360 | $5.70 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,223 | $3.57 |
| 0124A | <1% | 79 | $2.02 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,957 | $1.20 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 990 | $0.95 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 209 | $0.91 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 901 | $0.56 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 770 | $0.25 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 417 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 767 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 276 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 4,363 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 34 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 5,566 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 625 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 848 | $0.00 |
| A9270 | Non-covered item or service | 0% | 9,666 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 544 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 924 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 133 | $0.00 |
| 0754T | 0% | 41 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 108 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 80 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 97 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 91 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 823 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 100 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 19 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 25 | $0.00 |
| 88300 | 0% | 41 | $0.00 | |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 21 | $0.00 |
| 73552 | 0% | 15 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 40 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 18 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 12 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 26 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| 92567 | 0% | 12 | $0.00 | |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 21 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 69 | $0.00 |
| 73090 | 0% | 17 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 14 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 18 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 47 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 24 | $0.00 |
| 0753T | 0% | 2,394 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 2,306 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 334 | $0.00 |
| 0752T | 0% | 286 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 510 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 373 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 343 | $0.00 |
| 0760T | 0% | 241 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 31 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 281 | $0.00 |
| 17110 | 0% | 15 | $0.00 | |
| 77080 | 0% | 141 | $0.00 | |
| 73140 | 0% | 23 | $0.00 | |
| A6250 | Skin sealants, protectants, moisturizers, ointments, any type, any size | 0% | 39 | $0.00 |
| 31575 | 0% | 12 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 312 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 27 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 58 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 49 | $0.00 |
| 0054A | 0% | 30 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 77 | $0.00 |
| 0761T | 0% | 46 | $0.00 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 19 | $0.00 |
| C2625 | Stent, non-coronary, temporary, with delivery system | 0% | 14 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 1,160 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 28 | $0.00 |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 12 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 28 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 16 | $0.00 |
| 76937 | 0% | 14 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 109 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 25 | $0.00 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 0% | 17 | $0.00 |
| 0003A | 0% | 16 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 20 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| 76642 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBORTNEM, MARK (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.